Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HepeX-C (XTL Biopharmaceuticals).

Guglielmo Borgia1

  • 1Department of Public Medicine and Social Security, Institute for Infectious Diseases-Ed 18, University of Naples Federico II, via S Pansini 5, 80131 Naples, Italy. borgia@unina.it

Current Opinion in Investigational Drugs (London, England : 2000)
|December 17, 2004
PubMed
Summary

XTL Biopharmaceuticals is developing HepeX-C, a novel antibody combination therapy for hepatitis C virus infection. Phase I trials of the combined antibodies are planned following earlier Phase II studies of a single antibody component.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry.

Journal of chemotherapy (Florence, Italy)·2022
Same author

Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.

Journal of hepatology·2020
Same author

The role of curcumin in liver diseases.

Archives of medical science : AMS·2019
Same author

Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease.

IDCases·2019
Same author

Use of colistin in adult patients: A cross-sectional study.

Journal of global antimicrobial resistance·2019
Same author

An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy.

Expert opinion on investigational drugs·2019

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a significant global health concern.
  • Current treatments for HCV have limitations, necessitating the development of new therapeutic strategies.
  • Antibody-based therapies offer a promising avenue for treating viral infections like HCV.

Purpose of the Study:

  • To evaluate HepeX-C, a combination of two monoclonal antibodies (HCV-AB68 and HCV-AB65), as a potential treatment for hepatitis C virus infection.
  • To advance the development of novel immunotherapies for HCV.

Main Methods:

  • Development of HepeX-C, a combination therapy comprising HCV-AB68 and HCV-AB65 antibodies.
  • Previous Phase II clinical trials were conducted using HCV-AB68 as a monotherapy.
  • Planning for a Phase I clinical study to assess the safety and tolerability of the HepeX-C antibody combination.

Main Results:

  • Phase II trials of HCV-AB68 alone have been completed.
  • XTL Biopharmaceuticals has announced plans for a Phase I study of the HepeX-C antibody combination.

Conclusions:

  • The antibody combination HepeX-C shows potential as a future therapy for hepatitis C.
  • Further clinical investigation through Phase I trials is warranted to assess the safety and efficacy of HepeX-C.

Related Experiment Videos